Jianmei Wei

This inventor holds 39 USPTO granted patents and 5 published patent applications, plus 5 CIPO patents and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Janssen Pharmaceutica Nv, Ortho-Mcneil Pharmaceutical Corp., Bristol-Myers Squibb Compnay. Active years: 1998-2024.

USPTO Granted Patents = 39 (Patent Applications = 5)

% Patents Active = 89.7

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 8.7

ph-index = 6

Forward Citations = 116(Granted Patents)

Location History:

East Hartford, CT (US) (1998 - 2003)
San Diego, CA (US) (2001 - 2024)

Company Filing History:

17 out of 2,099

Janssen Pharmaceutica Nv

patents

15 out of 363

Ortho-Mcneil Pharmaceutical Corp.

patents

3 out of 3,736

Bristol-Myers Squibb Compnay

patents

4. 1 out of 377

Ortho Pharmaceutical Corporation

patents

5. 3 out of 834,411

Other

patents

Years Active: 1998-2024

Loading Chart...

Areas of Expertise:

Bruton's Tyrosine Kinase

KEAP1-Nrf2 Interaction

Histamine H4 Modulators

Substituted Pyrazoles

Heterocyclic Compounds

Taxanes

2,4-Diaminopyrimidine

Pharmaceuticals

Allergy Treatments

Drug Development

Novel Compounds

Crystalline Complexes

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12065446 - Inhibitors of Bruton's tyrosine kinase and method of their use (2024-08-20),

2. 11897900 - Inhibitors of KEAP1-Nrf2 protein-protein interaction (2024-02-13),

3. 11427601 - Inhibitors of KEAP1-Nrf2 protein-protein interaction (2022-08-30),

4. 11319329 - Inhibitors of Bruton's tyrosine kinase and methods of their use (2022-05-03),

5. 10947252 - Inhibitors of KEAP1-Nrf2 protein-protein interaction (2021-03-16),

6. 10934310 - Inhibitors of Bruton's tyrosine kinase and method of their use (2021-03-02),

7. 10822348 - Inhibitors of Bruton's tyrosine kinase and methods of their use (2020-11-03),

8. 10800792 - Inhibitors of Bruton's tyrosine kinase and method of their use (2020-10-13),

9. 10717745 - Inhibitors of Bruton's tyrosine kinase and method of their use (2020-07-21),

10. 10689396 - Inhibitors of Bruton's tyrosine kinase and methods of their use (2020-06-23),

11. 10172856 - 2,4-diaminopyrimidine derivatives as histamine H4 modulators (2019-01-08),

12. 9732087 - [object Object] (2017-08-15),

13. 8841287 - Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor (2014-09-23),

14. 8686142 - 2-aminopyrimidine modulators of the histamine H4 receptor (2014-04-01),

15. 7772236 - Substituted pyrazoles (2010-08-10),

Title: Inventor Spotlight: Jianmei Wei - Pioneering Pharmacologist from San Diego

Introduction:

Jianmei Wei, a distinguished inventor hailing from the vibrant city of San Diego, CA, has made significant contributions in the field of pharmacology. With an impressive portfolio of 38 patents to his name, Jianmei Wei's work has been pivotal in developing innovative solutions for treating various disease states and disorders.

Latest Patents:

Among his recent patents, Jianmei Wei has notably developed inhibitors of the KEAP1-Nrf2 protein-protein interaction - Sultam compounds. These pharmaceutical compositions exhibit great promise in treating inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. His patents encompass methods for creating these compounds, their applications, and their efficacy in addressing a range of conditions associated with the KEAP1-Nrf2 interaction.

Career Highlights:

Jianmei Wei has lent his expertise to renowned pharmaceutical companies such as Janssen Pharmaceutica and Ortho-McNeil Pharmaceutical Corp. His innovative research and patent developments have propelled these organizations towards pioneering advancements in the healthcare industry. Wei's relentless pursuit of excellence has been instrumental in shaping the landscape of modern pharmacology.

Collaborations:

Throughout his career, Jianmei Wei has collaborated with esteemed professionals in the field, including colleagues like James Patrick Edwards and Hui Cai. Together, they have synergized their expertise to drive forward groundbreaking research initiatives and develop novel therapeutic solutions. Wei's collaborative spirit underscores his commitment to fostering innovation through collective effort.

Conclusion:

In conclusion, Jianmei Wei stands as a beacon of innovation in the realm of pharmacology, with his groundbreaking patents and prolific career trajectory showcasing his unwavering dedication to advancing healthcare solutions. His contributions continue to inspire and pave the way for future advancements in the field.